Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Pancreatic Cancer Resectable 1Ovarian Carcinosarcoma 1Neoplasms 1Liver Neoplasms 1Immune-related Adverse Event 1Esophageal Neoplasms 1Early Hormone Receptor-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Bevacizumab 9pembrolizumab 5lenvatinib 5durvalumab 5atezolizumab 5tremelimumab 3fludarabine 3camrelizumab 3apatinib 3Ipilimumab 3Cyclophosphamide 3regorafenib 2Riluzole 2Radiotherapy 2Nivolumab 2Magnetic Resonance Imaging 2Idarubicin 2Blood Specimen Collection 2Biopsy 2yttrium chloride 1trastuzumab deruxtecan 1spartalizumab 1sintilimab 1pertuzumab 1ferric carboxymaltose 1epigallocatechin gallate 1donafenib 1cemiplimab 1brodalumab 1Yttrium-90 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liver Neoplasms × Antineoplastic Agents × Clear all
NCT06777485 2025-08-20

China Liver Cancer Clinical Registry Cohort Database (HEAL)

Anhui Provincial Hospital

Recruiting
10,000 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡